Clinical Trials Browser

Active not recruiting × Interventional × ribociclib × Clear all

NCT02934568 2026-04-16

Ribociclib (LEE011) Rollover Study for Continued Access

Phase 2 Active not recruiting

Other solid neoplasm

Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

NCT04920708 2026-04-14

FAIM

Phase 2 Active not recruiting

Breast Neoplasms

NCT05358249 2026-04-14

KontRASt-03

Phase 1/2 Active not recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4 Active not recruiting

Breast Neoplasms

NCT01872260 2026-04-01

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT03701334 2026-04-01

NATALEE

Phase 3 Active not recruiting

5,101 enrolled 5 FDA

Breast Neoplasms

NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Phase 2 Active not recruiting

Melanoma

NCT02712723 2026-03-11

FELINE

Phase 2 Active not recruiting

121 enrolled 9 charts

Breast Neoplasms

NCT05573555 2026-03-09

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT02933736 2026-03-06

Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

Phase EARLY_PHASE1 Active not recruiting

Glioblastoma, Meningioma

NCT03008408 2026-02-11

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase 2 Active not recruiting

Endometrial Neoplasms

NCT03616587 2026-01-28

SERENA-1

Phase 1 Active not recruiting

Breast Neoplasms

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase 1 Active not recruiting

EGFR-mutant Non-small Cell Lung Cancer

NCT04964934 2026-01-16

SERENA-6

Phase 3 Active not recruiting

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

Breast Neoplasms

NCT03090165 2026-01-02

Ribociclib and Bicalutamide in AR+ TNBC

Phase 1/2 Active not recruiting

Triple Negative Breast Neoplasms

NCT03673124 2025-12-23

Ribociclib and Letrozole Treatment in Ovarian Cancer

Phase 2 Active not recruiting

51 enrolled 19 charts

Cystadenocarcinoma, Serous

NCT03285412 2025-12-22

LEADER

Phase 2 Active not recruiting

Breast Neoplasms

NCT03740334 2025-11-21

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Phase 1 Active not recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03283384 2025-09-19

NEOLBC

Phase 2 Active not recruiting

Breast Neoplasms

NCT02608216 2025-09-03

[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer

Phase 1 Active not recruiting

Breast Neoplasms

NCT04055493 2025-08-26

ADAPTcycle

Phase 3 Active not recruiting

Breast Neoplasms

NCT05625087 2025-08-20

SAFIR 03

Phase 2 Active not recruiting

Breast Neoplasms

NCT05207709 2025-04-29

HARMONIA

Phase 3 Active not recruiting

Breast Neoplasms

NCT03114527 2025-04-04

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Phase 2 Active not recruiting

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT03944434 2025-02-26

FACILE

Phase 2 Active not recruiting

Breast Neoplasms

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

Phase 3 Active not recruiting

Breast Neoplasms